These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

638 related items for PubMed ID: 28700265

  • 21. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y, Kimachi K, Okada Y, Matsuura K, Ooyama Y, Ibaragi K, Kino Y, Ueda K.
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [Abstract] [Full Text] [Related]

  • 22. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China.
    Wang SY, Liu SZ, Chu K, Zhao Y, Zhu FC, Hu YM, Meng FY, Li JX, Luo L, Yang JY, Liu P, Yu J.
    Expert Rev Vaccines; 2017 Nov; 16(11):1155-1169. PubMed ID: 28870140
    [Abstract] [Full Text] [Related]

  • 23. Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study.
    Bart S, Cannon K, Herrington D, Mills R, Forleo-Neto E, Lindert K, Abdul Mateen A.
    Hum Vaccin Immunother; 2016 Sep; 12(9):2278-88. PubMed ID: 27322354
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India.
    Agarkhedkar S, Chhatwal J, Kompithra RZ, Lalwani SK, Narayan A, Muninarayanaswam V, Gogtay N, Dotter K, Gresset-Bourgeois V.
    Hum Vaccin Immunother; 2019 Sep; 15(4):973-977. PubMed ID: 30762467
    [Abstract] [Full Text] [Related]

  • 27. Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial.
    Pepin S, Nicolas JF, Szymanski H, Leroux-Roels I, Schaum T, Bonten M, Icardi G, Shrestha A, Tabar C, QHD00011 study team.
    Hum Vaccin Immunother; 2021 Dec 02; 17(12):5475-5486. PubMed ID: 34714720
    [Abstract] [Full Text] [Related]

  • 28. Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil.
    Zerbini CA, Ribeiro Dos Santos R, Jose Nunes M, Soni J, Li P, Jain VK, Ofori-Anyinam O.
    Braz J Infect Dis; 2017 Dec 02; 21(1):63-70. PubMed ID: 27912069
    [Abstract] [Full Text] [Related]

  • 29. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial.
    Sanchez L, Matsuoka O, Inoue S, Inoue T, Meng Y, Nakama T, Kato K, Pandey A, Chang LJ.
    Hum Vaccin Immunother; 2020 Apr 02; 16(4):858-866. PubMed ID: 31634025
    [Abstract] [Full Text] [Related]

  • 30. Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults.
    Claeys C, Drame M, García-Sicilia J, Zaman K, Carmona A, Tran PM, Miranda M, Martinón-Torres F, Thollot F, Horn M, Schwarz TF, Behre U, Merino JM, Sadowska-Krawczenko I, Szymański H, Schu P, Neumeier E, Li P, Jain VK, Innis BL.
    BMC Infect Dis; 2018 Apr 18; 18(1):186. PubMed ID: 29669531
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial.
    Chen H, Huang Z, Chang S, Hu M, Lu Q, Zhang Y, Wang H, Xiao Y, Wang H, Ge Y, Zou Y, Cui F, Han S, Zhang M, Wang S, Zhu X, Zhang B, Li Z, Ren J, Chen X, Ma R, Zhang L, Guo X, Luo L, Sun X, Yang X.
    Vaccine; 2022 Aug 26; 40(36):5322-5332. PubMed ID: 35931636
    [Abstract] [Full Text] [Related]

  • 33. Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.
    Shinde V, Cho I, Plested JS, Agrawal S, Fiske J, Cai R, Zhou H, Pham X, Zhu M, Cloney-Clark S, Wang N, Zhou B, Lewis M, Price-Abbott P, Patel N, Massare MJ, Smith G, Keech C, Fries L, Glenn GM.
    Lancet Infect Dis; 2022 Jan 26; 22(1):73-84. PubMed ID: 34563277
    [Abstract] [Full Text] [Related]

  • 34. High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults.
    Chahine EB.
    Ann Pharmacother; 2021 Jan 26; 55(1):89-97. PubMed ID: 32578447
    [Abstract] [Full Text] [Related]

  • 35. Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial.
    Chang LJ, Anderson EJ, Jeanfreau R, He Y, Hicks B, Shrestha A, Pandey A, Landolfi V, DeBruijn I, QHD04 Study Group.
    Vaccine; 2021 Mar 12; 39(11):1572-1582. PubMed ID: 33610374
    [Abstract] [Full Text] [Related]

  • 36. Quadrivalent inactivated influenza vaccine (VaxigripTetra™).
    Gresset-Bourgeois V, Leventhal PS, Pepin S, Hollingsworth R, Kazek-Duret MP, De Bruijn I, Samson SI.
    Expert Rev Vaccines; 2018 Jan 12; 17(1):1-11. PubMed ID: 29157068
    [Abstract] [Full Text] [Related]

  • 37. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA, Saway W, Gouaux J, Baron M, Baker J, Denis M, Jordanov E, Landolfi V, Yau E.
    Vaccine; 2015 Dec 16; 33(51):7188-7193. PubMed ID: 26555348
    [Abstract] [Full Text] [Related]

  • 38. Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study.
    Fan R, Huang X, Nian X, Ou Z, Zhou J, Zhang J, Zeng P, Zhao W, Deng J, Chen W, Chen S, Duan K, Chen Y, Li X, Zhang J, Yang X.
    Hum Vaccin Immunother; 2022 Dec 31; 18(1):1-9. PubMed ID: 34473607
    [Abstract] [Full Text] [Related]

  • 39. Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial.
    Sharma S, Singh VB, Kumar S, Prajapati V, Patel J, Vukkala R, Jangid SK, Sanmukhani J, Gupta G, Patel P, Mittal R, Glueck R.
    Hum Vaccin Immunother; 2018 Jun 03; 14(6):1362-1369. PubMed ID: 29461913
    [Abstract] [Full Text] [Related]

  • 40. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.
    Ofori-Anyinam O, Leroux-Roels G, Drame M, Aerssens A, Maes C, Amanullah A, Schuind A, Li P, Jain VK, Innis BL.
    Vaccine; 2017 Nov 01; 35(46):6321-6328. PubMed ID: 28987445
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.